No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes
CONCLUSION: Six months of treatment with 1.2 mg/day of liraglutide had no effect on the kinetics of HDL apoAI in patients with T2D. The lack of decrease in triglyceride content in HDL related to an only moderate decrease in triglyceridemia, probably greatly explains these results. Insufficient improvement of insulin sensitivity and adiponectinemia may also be implied.PMID:38653365 | DOI:10.1016/j.diabet.2024.101535 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - April 23, 2024 Category: Endocrinology Authors: Laurence Duvillard Jean-Paul Pais de Barros Alexia Rouland Isabelle Simoneau Damien Denimal Benjamin Bouillet Jean-Michel Petit Bruno Verg ès Source Type: research
No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes
CONCLUSION: Six months of treatment with 1.2 mg/day of liraglutide had no effect on the kinetics of HDL apoAI in patients with T2D. The lack of decrease in triglyceride content in HDL related to an only moderate decrease in triglyceridemia, probably greatly explains these results. Insufficient improvement of insulin sensitivity and adiponectinemia may also be implied.PMID:38653365 | DOI:10.1016/j.diabet.2024.101535 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - April 23, 2024 Category: Endocrinology Authors: Laurence Duvillard Jean-Paul Pais de Barros Alexia Rouland Isabelle Simoneau Damien Denimal Benjamin Bouillet Jean-Michel Petit Bruno Verg ès Source Type: research
No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes
CONCLUSION: Six months of treatment with 1.2 mg/day of liraglutide had no effect on the kinetics of HDL apoAI in patients with T2D. The lack of decrease in triglyceride content in HDL related to an only moderate decrease in triglyceridemia, probably greatly explains these results. Insufficient improvement of insulin sensitivity and adiponectinemia may also be implied.PMID:38653365 | DOI:10.1016/j.diabet.2024.101535 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - April 23, 2024 Category: Endocrinology Authors: Laurence Duvillard Jean-Paul Pais de Barros Alexia Rouland Isabelle Simoneau Damien Denimal Benjamin Bouillet Jean-Michel Petit Bruno Verg ès Source Type: research
Association between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction: A 7-year retrospective cohort study of 3,380 adults using serial echocardiography
CONCLUSIONS: This study demonstrated that NAFLD was associated with an increased risk of LVDD in a large cohort. More severe forms of hepatic steatosis and/or significant liver fibrosis may increase the risk of developing LVDD.PMID:38608865 | DOI:10.1016/j.diabet.2024.101534 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - April 12, 2024 Category: Endocrinology Authors: Gyuri Kim Tae Yang Yu Jae Hwan Jee Ji Cheol Bae Mira Kang Jae Hyeon Kim Source Type: research
Association between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction: A 7-year retrospective cohort study of 3,380 adults using serial echocardiography
CONCLUSIONS: This study demonstrated that NAFLD was associated with an increased risk of LVDD in a large cohort. More severe forms of hepatic steatosis and/or significant liver fibrosis may increase the risk of developing LVDD.PMID:38608865 | DOI:10.1016/j.diabet.2024.101534 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - April 12, 2024 Category: Endocrinology Authors: Gyuri Kim Tae Yang Yu Jae Hwan Jee Ji Cheol Bae Mira Kang Jae Hyeon Kim Source Type: research
Association between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction: A 7-year retrospective cohort study of 3,496 adults using serial echocardiography
CONCLUSIONS: This study demonstrated that NAFLD was associated with an increased risk of LVDD in a large cohort. More severe forms of hepatic steatosis and/or significant liver fibrosis may increase the risk of developing LVDD.PMID:38608865 | DOI:10.1016/j.diabet.2024.101534 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - April 12, 2024 Category: Endocrinology Authors: Gyuri Kim Tae Yang Yu Jae Hwan Jee Ji Cheol Bae Mira Kang Jae Hyeon Kim Source Type: research
Association between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction: A 7-year retrospective cohort study of 3,496 adults using serial echocardiography
CONCLUSIONS: This study demonstrated that NAFLD was associated with an increased risk of LVDD in a large cohort. More severe forms of hepatic steatosis and/or significant liver fibrosis may increase the risk of developing LVDD.PMID:38608865 | DOI:10.1016/j.diabet.2024.101534 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - April 12, 2024 Category: Endocrinology Authors: Gyuri Kim Tae Yang Yu Jae Hwan Jee Ji Cheol Bae Mira Kang Jae Hyeon Kim Source Type: research
Association between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction: A 7-year retrospective cohort study of 3,496 adults using serial echocardiography
CONCLUSIONS: This study demonstrated that NAFLD was associated with an increased risk of LVDD in a large cohort. More severe forms of hepatic steatosis and/or significant liver fibrosis may increase the risk of developing LVDD.PMID:38608865 | DOI:10.1016/j.diabet.2024.101534 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - April 12, 2024 Category: Endocrinology Authors: Gyuri Kim Tae Yang Yu Jae Hwan Jee Ji Cheol Bae Mira Kang Jae Hyeon Kim Source Type: research
Association between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction: A 7-year retrospective cohort study of 3,496 adults using serial echocardiography
CONCLUSIONS: This study demonstrated that NAFLD was associated with an increased risk of LVDD in a large cohort. More severe forms of hepatic steatosis and/or significant liver fibrosis may increase the risk of developing LVDD.PMID:38608865 | DOI:10.1016/j.diabet.2024.101534 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - April 12, 2024 Category: Endocrinology Authors: Gyuri Kim Tae Yang Yu Jae Hwan Jee Ji Cheol Bae Mira Kang Jae Hyeon Kim Source Type: research
Association between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction: A 7-year retrospective cohort study of 3,496 adults using serial echocardiography
CONCLUSIONS: This study demonstrated that NAFLD was associated with an increased risk of LVDD in a large cohort. More severe forms of hepatic steatosis and/or significant liver fibrosis may increase the risk of developing LVDD.PMID:38608865 | DOI:10.1016/j.diabet.2024.101534 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - April 12, 2024 Category: Endocrinology Authors: Gyuri Kim Tae Yang Yu Jae Hwan Jee Ji Cheol Bae Mira Kang Jae Hyeon Kim Source Type: research
No association of endothelial lipase and aldose reductase polymorphisms with proliferative diabetic retinopathy: Results of the French prospective multicenter REDIAGEN study
Diabetes Metab. 2024 Apr 1;50(3):101533. doi: 10.1016/j.diabet.2024.101533. Online ahead of print.NO ABSTRACTPMID:38570135 | DOI:10.1016/j.diabet.2024.101533 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - April 3, 2024 Category: Endocrinology Authors: Adrien Henry Tiffany Boigelot Thomas Ferreira DE Moura Isabelle Leclercq Coralie Barbe Aurore Thiery Zoubir Djerada Pierre Nazeyrollas Christine Clavel Pascale Cornillet-Lefebvre Jean-Paul Berrod Catherine Creuzot-Garcher Laurent Meyer David Gaucher Bruno Source Type: research
No association of endothelial lipase and aldose reductase polymorphisms with proliferative diabetic retinopathy: Results of the French prospective multicenter REDIAGEN study
Diabetes Metab. 2024 Apr 1;50(3):101533. doi: 10.1016/j.diabet.2024.101533. Online ahead of print.NO ABSTRACTPMID:38570135 | DOI:10.1016/j.diabet.2024.101533 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - April 3, 2024 Category: Endocrinology Authors: Adrien Henry Tiffany Boigelot Thomas Ferreira DE Moura Isabelle Leclercq Coralie Barbe Aurore Thiery Zoubir Djerada Pierre Nazeyrollas Christine Clavel Pascale Cornillet-Lefebvre Jean-Paul Berrod Catherine Creuzot-Garcher Laurent Meyer David Gaucher Bruno Source Type: research
No association of endothelial lipase and aldose reductase polymorphisms with proliferative diabetic retinopathy: Results of the French prospective multicenter REDIAGEN study
Diabetes Metab. 2024 Apr 1;50(3):101533. doi: 10.1016/j.diabet.2024.101533. Online ahead of print.NO ABSTRACTPMID:38570135 | DOI:10.1016/j.diabet.2024.101533 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - April 3, 2024 Category: Endocrinology Authors: Adrien Henry Tiffany Boigelot Thomas Ferreira DE Moura Isabelle Leclercq Coralie Barbe Aurore Thiery Zoubir Djerada Pierre Nazeyrollas Christine Clavel Pascale Cornillet-Lefebvre Jean-Paul Berrod Catherine Creuzot-Garcher Laurent Meyer David Gaucher Bruno Source Type: research
No association of endothelial lipase and aldose reductase polymorphisms with proliferative diabetic retinopathy: results of the French prospective multicenter REDIAGEN study
Diabetes Metab. 2024 Apr 1:101533. doi: 10.1016/j.diabet.2024.101533. Online ahead of print.NO ABSTRACTPMID:38570135 | DOI:10.1016/j.diabet.2024.101533 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - April 3, 2024 Category: Endocrinology Authors: Adrien Henry Tiffany Boigelot Thomas Ferreira DE Moura Isabelle Leclercq Coralie Barbe Aurore Thiery Zoubir Djerada Pierre Nazeyrollas Christine Clavel Pascale Cornillet-Lefebvre Jean-Paul Berrod Catherine Creuzot-Garcher Laurent Meyer David Gaucher Bruno Source Type: research
No association of endothelial lipase and aldose reductase polymorphisms with proliferative diabetic retinopathy: results of the French prospective multicenter REDIAGEN study
Diabetes Metab. 2024 Apr 1:101533. doi: 10.1016/j.diabet.2024.101533. Online ahead of print.NO ABSTRACTPMID:38570135 | DOI:10.1016/j.diabet.2024.101533 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - April 3, 2024 Category: Endocrinology Authors: Adrien Henry Tiffany Boigelot Thomas Ferreira DE Moura Isabelle Leclercq Coralie Barbe Aurore Thiery Zoubir Djerada Pierre Nazeyrollas Christine Clavel Pascale Cornillet-Lefebvre Jean-Paul Berrod Catherine Creuzot-Garcher Laurent Meyer David Gaucher Bruno Source Type: research
